^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Halaven (eribulin mesylate)

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Eisai, Knight Therap, Shenzhen Kexing Pharma
    Drug class:
    Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor
    Related drugs:
    3d
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
    5d
    OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    9d
    LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=30, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Halaven (eribulin mesylate)
    16d
    Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (PubMed, World J Surg Oncol)
    This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-H • PD-L1 negative
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • pazopanib • Halaven (eribulin mesylate)
    16d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=580 --> 792 | Trial completion date: May 2028 --> Sep 2030 | Trial primary completion date: May 2028 --> Sep 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PD-L1 expression • PIK3CA mutation
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    23d
    A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. (clinicaltrials.gov)
    P2, N=95, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 | N=66 --> 95 | Trial completion date: May 2028 --> Dec 2028 | Initiation date: Apr 2025 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Dec 2027
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Halaven (eribulin mesylate)
    24d
    ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HER-2 expression
    |
    Halaven (eribulin mesylate) • Ontruzant (trastuzumab-dttb)
    26d
    DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov)
    P=N/A, N=1155, Recruiting, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Trial primary completion date: Jun 2027 --> Sep 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    27d
    BL-B01D1-307: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=418, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    1m
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    1m
    Predicting the Efficacy of Eribulin in Metastatic Breast Cancer by Assessing E-Cadherin and Vimentin Expression. (PubMed, Acta Histochem Cytochem)
    Altered E-cadherin and/or vimentin expression was more frequently observed in responders (p = 0.013) and associated with longer progression-free survival (p = 0.048). These results suggest that eribulin efficacy may be predicted by altered E-cadherin and vimentin expression before treatment.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin)
    |
    Halaven (eribulin mesylate)
    1m
    A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P1
    Phase classification
    |
    temozolomide • irinotecan • Halaven (eribulin mesylate)